Article
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Feb 2020
Mazieres J, Cropet C, Montané L, Barlesi F, Souquet P J, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti G R, Tiffon C, Mahier-Ait Oukhatar C, Blay J Y
Abstract excerpt
BACKGROUND: BRAF mutations occurring in 1%-5% of patients with non-small-cell lung cancer (NSCLC) are therapeutic targets for these cancers but the impact of the exact mutation on clinical activity is unclear. The French National Cancer Institute (INCA) launched the AcSé vemurafenib trial to assess the efficacy and safety of vemurafenib in cancers with various BRAF mutations. We herein report the results of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.